Break it Down: Radiopharm Theranostics progresses along path to help heal HER-2 cancer

Link copied to
clipboard

Stockhead’s Break it Down brings you today’s leading market news in under 90 seconds.

In this episode, host Sarah Hughan tells all on Radiopharm Theranostics’ (ASX:RAD) approval to begin its first in-human study for the treatment of breast and gastric cancers with its novel radiotherapeutic.

The trial is designed to evaluate the safety and preliminary clinical activity of the treatment in individuals with HER2-expressing solid tumours with potential to address an unmet treatment gap.

Tune in to get the latest.

share

• 
• 
• 
• 

Link copied to
clipboard

SUBSCRIBE

Get the latest Stockhead news delivered free to your inbox.

Name*

Email*

This field is hidden when viewing the form

Email Lists

Morning Update

Lunch Update

Market Close Update

Weekend Update

Spotlight

Phone

This field is for validation purposes and should be left unchanged.

It's free. Unsubscribe whenever you want.

By proceeding, you confirm you understand that we handle personal information in accordance with our Privacy Policy.

You might be interested in

Stockhead TV

Tony's Takeaway: Biotech buffet on the ASX

October 7, 2024 | Tony Locantro

V-Cons

V-Con: Tim Boreham's Hot Stock Picks for 2022

February 9, 2022 | Stockhead TV

Trending

Health & Biotech

Lumos starts ‘pivotal clinical study’ in US for point-of-care respiratory test

December 20, 2024 | Special Report